找到相关结果： 824

Blocklisting Six Monthly Return

London: Friday, June 29, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of scheme: (a)

公告及新闻稿, 新闻稿, 集团 | 2018-06-29

Chi-Med to Announce 2018 Half-Year Financial Results

London: Friday, June 29, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2018 on Friday, July 27, 2018 at 7:00 am British Summer Time (BST). An analy

演示文稿, 科学出版物 | 2018-06-26

JAMA: Fruquintinib vs Placebo in Previously Treated Metastatic Colorectal Cancer

Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer The FRESCO Randomized Clinical Trial Jin Li; Shukui Qin; Rui-Hua Xu; Lin Shen; Jianming Xu; Yuxian Bai; Lei Yang; Yanhong Deng;

公告及新闻稿, 监管通知 | 2018-06-07

Grant of Share Options under Share Option Scheme

London: Thursday, June 7, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on June 6, 2018, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Meeting i

公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2018-06-04

和黄医药在2018年ASCO年会上公布呋喹替尼FRESCO研究更多研究数据

1 个附件

-继2017年ASCO年会上就FRESCO研究达到全部研究终点，呋喹替尼安全性良好，较其他靶向疗法脱靶毒性更低等数据进行口头报告后，和黄医药在2018年ASCO年会上公布了FRESCO研究进一步的研究数据-

下载新闻稿 (PDF)

演示文稿, 科学出版物 | 2018-06-04

ASCO 2018: Colorectal cancer Q-TWiST with fruquintinib treatment in FRESCO

Quality-adjusted time without symptoms or toxicity (Q-TWiST) of patients with metastatic colorectal cancer treated with fruquintinib in FRESCO Presenter: Yu-Xian Bai Other Authors: Hongyan Li, Ning Wang, Xiaojun Guo, Wei Wang, Songhua F

演示文稿, 科学出版物 | 2018-06-04

ASCO 2018: Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO

Presenter: Ruihua Xu Other Authors: Jin Li, Yu-Xian Bai, Yanhong Deng, Lei Yang, Haijun Zhong, Zhendong Chen, Hongming Pan, Weijian Guo, Yongqian Shu, Ying Yuan, Jianming Xu, Lin Shen, Ning Wang, Xin Wang, Haidong Chi, Jack Peng, Y

公告及新闻稿, 监管通知 | 2018-05-31

Total Voting Rights

London: Thursday, May 31, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at May 31, 2018, the issued share capital of Chi-Med consisted of 66,515,756 ordinary shares of US$1.00 each, with e

公告及新闻稿, 新闻稿, 集团 | 2018-05-11

Chi-Med to Present at Bank of America Merrill Lynch Annual Health Care Conference

Press Release London: Friday, May 11, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced today that Christian Hogg, Chief Executive Officer, will present at the Bank of America Merrill Lynch 2018 Health Care Confe

公告及新闻稿, 监管通知 | 2018-04-30

Total Voting Rights

London: Monday, April 30, 2018: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at April 30, 2018, the issued share capital of Chi-Med consisted of 66,484,620 ordinary sh

公告及新闻稿, 监管通知 | 2018-04-27

Results of AGM Meeting

London: Friday, April 27, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that all ordinary resolutions and special resolutions put to its Annual General Meeting (“AGM”) held on April 27, 2018 were duly pa

公告及新闻稿, 监管通知 | 2018-04-23

Block Admission

London: Monday, April 23, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that an application has been made to the London Stock Exchange plc for a block admission of 1,425,597 ordinary shares, par value of US$

公告及新闻稿, 监管通知 | 2018-04-23

Grant of Share Options under Share Option Scheme

London: Monday, April 23, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on April 20, 2018, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Meeting

演示文稿, 科学出版物 | 2018-04-17

AACR 2018: MET gene copy number gains evaluated by NGS is more predictive than other methods to enrich for papillary RCC patients sensitive to savolitinib

4541 / 26 - MET gene copy number gains evaluated by NGS is more predictive than other methods to enrich for papillary RCC patients sensitive to savolitinib, a selective MET inhibitor Presenter/Authors M. M. Frigault1, S. Signoretti2, A. Markovets

公告及新闻稿, 监管通知 | 2018-03-29

Total Voting Rights

London: Thursday, March 29, 2018: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at March 29, 2018, the issued share capital of Chi-Med consisted of 66,476,279 ordinary

公告及新闻稿, 监管通知 | 2018-03-28

Vesting of awards under the Long Term Incentive Plan

London: Wednesday, March 28, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that following the publication of the 2017 annual report of Chi-Med on March 26, 2018, the following awards granted under the Long Term In

公告及新闻稿, 集团 | 2018-03-26

2017 Annual Report and Notice of Annual General Meeting

London: Monday, March 26, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that its 2017 Annual Report together with the Notice of Annual General Meeting and the Form of Proxy have been posted to shareholders.�

演示文稿, 科学出版物 | 2018-03-23

ASCPT 2018: Fruquintinib Pharmacokinetics in Humans

Pharmacokinetics of Fruquintinib in Humans Venue: American Society for Clinical Pharmacology & Therapeutics Annual Meeting in Orlando, Florida, USA Abstract #: PII-116 Authors: Ke Li, Chen Yu, Yanmei Liu, Xiangkun Li, Sumei Xia, Jian Wa

公告及新闻稿, 监管通知 | 2018-03-21

Director’s Share Dealing

London: Wednesday, March 21, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that the spouse of Mr Graeme Jack, Independent Non-executive Director, purchased a total of 3,000 American Depositary Shar

公告及新闻稿, 监管通知 | 2018-03-20

Grant of Share Options under Share Option Scheme

London: Tuesday, March 20, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on March 19, 2018, it granted share options under the Share Option Scheme adopted by Chi-Med at its Annual General Meeting on April 24,

公告及新闻稿, 监管通知 | 2018-03-19

Director's Share Dealing

London: Monday, March 19, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notification that Dr Dan Eldar, Non-executive Director, purchased a total of 2,768 American Depositary Shares of the Company (“ADSs”,

公告及新闻稿, 集团 | 2018-03-12

Publication of Form 20-F for the Year Ended December 31, 2017

公告及新闻稿, 集团 | 2018-03-12

Chi-Med Reports Final Results for the Year Ended December 31, 2017 and Updates Shareholders on Key Clinical Programs

Hutchison China MediTech Limited (“Chi-Med”) Reports Final Results for the Year Ended December 31, 2017 and Updates Shareholders on Key Clinical Programs Group: Year of major progress; results in line with guidance Group revenue up 12% to $

演示文稿, 科学出版物 | 2018-03-12

Journal of Clinical Oncology: Phase II Trial of Fruquintinib in Patients with Advanced Nonsquamous NSCLC

Shun Lu, Jianhua Chang, Xiaoqing Liu, Jianhua Shi, You Lu, Wei Li, Jin-ji Yang, Jianying Zhou, Jie Wang, Tongtong An, Lei Yang, Zhe Liu, Xiangdong Zhou, Mo Chen, Ye Hua and Weiguo Su Abstract Purpose Patients with advanced non‒small-cell lung

公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2018-03-06

和黄医药在中国启动依吡替尼以胶质母细胞瘤为适应症的Ib/II期概念验证临床试验

1 个附件

2018年3月6日: 和黄医药今日宣布在中国启动依吡替尼Ib/II期概念验证临床试验，目标受试者为表皮生长因子受体（EGFR）基因扩增的胶质母细胞瘤患者。胶质母细胞瘤是脑肿瘤的一种主要类型�

下载新闻稿 (PDF)

演示文稿, 科学出版物 | 2018-02-24

ACOS 2018: Adverse Events of Special Interest Profiles and Time Courses of Fruquintinib in the FRESCO Trial

Venue: The 13th International Conference of the Asian Clinical Oncology Society in Chiang Mai, Thailand Abstract #: ABS093 Authors: Jin Li, Shukui Qin, Yuxian Bai, Yanhong Deng, Lei Yang, Zhendong Chen, Haijun Zhong, Rui-hua Xu, Hongming Pan,

演示文稿, 科学出版物 | 2018-02-20

ICTO2018: Phase Ib of Savolitinib and Durvalumab in Renal Cell Carcinoma (CALYPSO)

A Phase Ib Study of Durvalumab (MEDI4736) in Combination with Savolitinib in Patients with Metastatic Renal Cell Carcinoma S Vari1, B Szabados1, A GomezdeLiano1, K Mousa2, L Rammazzo2, A Prendergast2, T Powles1 1 Barts Health NHS Trust, Barts Can

公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2018-02-13

和黄医药完成呋喹替尼以非小细胞肺癌为适应症的III期临床试验的患者入组工作，共招募527名患者

1 个附件

2018年2月13日：和黄医药今日宣布呋喹替尼（HMPL-013）以非小细胞肺癌为适应症的III期临床试验“FALUCA”顺利完成患者入组工作。呋喹替尼是一种高选择性强效口服血管内皮生长因子受体（VEGF

下载新闻稿 (PDF)

公告及新闻稿, 监管通知 | 2018-02-05

Chi-Med to Announce 2017 Final Results

London: Monday, February 5, 2018: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its final results for the year ended December 31, 2017 on Monday, March 12, 2018 at 7:00 am Greenwich Mean Time (GMT). An analy

公告及新闻稿, 监管通知 | 2017-12-29

Total Voting Rights

London: Friday, December 29, 2017: For information purposes, Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at December 29, 2017, the issued share capital of Chi-Med consisted of 66,447,037 ordin

公告及新闻稿, 监管通知 | 2017-12-29

Blocklisting Six Monthly Return

London: Friday, December 29, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return: 1. Name of applicant: Hutchison China MediTech Limited 2. Name of scheme: H

公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-12-15

和黄医药在美国启动呋喹替尼临床试验

1 个附件

2017年12月15日：和黄医药今日宣布在美国启动呋喹替尼I期桥接临床试验。呋喹替尼是一种高选择性强效口服血管内皮生长因子受体（VEGFR）1,2及3的抑制剂。呋喹替尼在中国以结直肠癌、肺癌�

下载新闻稿 (PDF)

公告及新闻稿, 监管通知 | 2017-11-01

TR-1: Notification of major interest in shares

公告及新闻稿, 监管通知 | 2017-11-01

TR-1: Notification of major interest in shares

公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-10-31

和黄医药启动呋喹替尼以二线胃癌为适应症的III期临床研究FRUTIGA

1 个附件

2017年10月31日：和黄医药今日宣布在中国启动呋喹替尼联合紫杉醇（泰素®）以晚期胃癌或胃食管结合部（GEJ）腺癌为适应症的关键性III期临床研究，这项研究被命名为FRUTIGA 。呋喹替尼是一�

下载新闻稿 (PDF)

公告及新闻稿, 集团 | 2017-10-30

Chi-Med Announces the Closing of U.S. Public Offering of American Depositary Shares (ADSs) Raising Approximately US$301.3 Million on the Nasdaq Global Select Market

London: Monday, October 30, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced today the closing of its underwritten public offering of American Depositary Shares ("ADSs") on the Nasdaq Global Select Market, previously

公告及新闻稿, 集团 | 2017-10-27

Chi-Med Announces the Full Exercise of Underwriters' Over-allotment Option

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: Friday, October 27, 2017: Hutchison China MediTech L

公告及新闻稿, 集团 | 2017-10-26

Chi-Med Announces Pricing of U.S. Public Offering of ADSs Raising US$262 Million on Nasdaq Global Select Market (RNS)

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: Wednesday, October 25, 2017: Hutchison China MediTec

新闻稿, 集团 | 2017-10-26

Chi-Med Announces Pricing of U.S. Public Offering of ADSs Raising US$262 Million on Nasdaq Global Select Market

London: Wednesday, October 25, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced today the pricing of the underwritten public offering previously announced by Chi-Med on October 24, 2017. Chi-Med will issue and sell 9

公告及新闻稿, 集团 | 2017-10-25

Chi-Med Announces Proposed Offering of ADSs (RNS)

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: Tuesday, October 24, 2017: Hutchison China MediTech

新闻稿, 集团 | 2017-10-24

Chi-Med Announces Proposed Offering of ADSs

London: Tuesday, October 24, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced today that it intends to offer, subject to market and other conditions, US$262.0 million of American Depositary Shares (“ADSs”), each

公告及新闻稿, 监管通知 | 2017-10-19

TR-1: Notification of major interest in shares

公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-10-17

和黄医药联合阿斯利康开发的沃利替尼二线治疗MET扩增的EGFR突变肺癌患者展现出良好的临床抗肿瘤活性

1 个附件

–沃利替尼联合泰瑞莎®或易瑞沙®的临床研究数据于世界肺癌大会公布– –新公布的数据有助于理解MET扩增的EGFR突变NSCLC的疾病进展过程和探索潜在的新一代治疗策略 – 2017�

下载新闻稿 (PDF)

演示文稿, 科学出版物 | 2017-10-17

WCLC 2017: Phase Ib/II savolitinib plus Iressa® in MET-driven NSCLC

OA 09.06 – A Phase Ib Trial of Savolitinib plus Gefitinib for Chinese Patients with EGFR-Mutant MET-Amplified Advanced NSCLC Jin-Ji Yang, Jian Fang, Y. Shu, J. Chang, G. Chen, J. He, W. Li, X. Liu, N. Yang, Caicun Zhou, J. Huang, L. Yang, A.A. Han

演示文稿, 科学出版物 | 2017-10-17

WCLC 2017: Phase Ib/II savolitinib plus Tagrisso® in MET-driven NSCLC

OA 09.03 – TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI Myung-Ju Ahn, Ji-Youn Han, Lecia V Sequist, Byoung Chul Cho, J.S. Lee, Sang-We Kim, W. Su, C. T

公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-10-16

和黄医药公布呋喹替尼联合疗法用于肺癌一线治疗的II期临床研究初步结果

1 个附件

– 呋喹替尼联合易瑞沙®（吉非替尼）展现出良好的疗效和安全性 – –进一步证实呋喹替尼因其高选择性和出众的安全性而具有与其他癌症疗法相联合的巨大潜力– 2017年10月1

下载新闻稿 (PDF)

演示文稿, 科学出版物 | 2017-10-15

WCLC 2017: Phase II fruquintinib combination with Iressa in NSCLC

JCSE 01.12 – A Phase II study of fruquintinib in combination with gefitinib in stage IIIb/IV NSCLC patients harboring EGFR activating mutations (NCT02976116) Shun Lu, Jianying Zhou, Xiaomin Niu, Mo Chen, Hongyan Yin, Ye Hua, Weiguo Su Venue: IA

公告及新闻稿, 新闻稿, 集团 | 2017-10-12

和黄医药董事会董事任命

1 个附件

2017年10月12日：和黄中国医药科技有限公司（简称“和黄医药”或“Chi-Med”）（纳斯达克/伦敦证交所：HCM）今日宣布任命莫树锦（Tony Mok）教授担任公司独立非执行董事，同时担任科学委员�

下载新闻稿 (PDF)

公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-09-29

Chi-Med Highlights Oral Presentations at CSCO Annual Meeting

Press Release – Three oral presentations given at CSCO for fruquintinib, savolitinib and theliatinib – – Plenary keynote presentation for FRESCO Phase III trial details analysis showing consistent survival benefit in all key subgroups

公告及新闻稿, 新闻稿, 肿瘤学 / 免疫学 | 2017-09-29

Chi-Med to Present Savolitinib and Fruquintinib Clinical Data at WCLC 2017 Annual Meeting

Press Release – Data to show potential of savolitinib to treat EGFR-TKI resistance in both Iressa® and Tagrisso® refractory patients with MET amplification – – Results to further validate Chi-Med’s scientific strategy of designing highly

1 2 3 4 5 6 7 8

10 11 12 13 14 15 16 17